Sativa Wellness Group #SWEL, the UK-based CBD business give London South East an operational update Watch Now
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Davde. My reading suggests that revenue will still be growing well after the launch of personal testing devices which grab headlines. My experience of biotech products which have revenue streams from consumables, undeveloped applications and global markets is very clear. The company will be acquired by a competitor. Skin will tick all the boxes but only after it has a product in the market.
Whilst the value of my investment may have gone down from the high, any gain /lose will only crystallize if I sell. To have lost significant money you would need to have been very unlucky and invested on tuesday or wed morning and sold out. Whilst l have sympathy for genuine investors l have none for traders chasing a quick buck. They know the risks and win some, lose some and some are very successful, others less so. It's the hot share traders that contribute volatility in a share just look at other Covid shares most have had significant volatility in last months as the money swills around on impending news. For long term holders most will be in paper profit even at the current price. You may regret not having cashed in buy heyho its not the end of the world. This share has some way to run in the coming months we need to wait and see.
Just to confirm I hold the same shares in MWG and SKIN today that I had on Wednesday, so I am 'one of those hundreds of people' whose investment was negatively affected.
I also have never claimed to know anything about anything let alone SKIN or MWG or Investing generally and consistently say DYOR and IMHO
All the best
Please read my post again? I said I personally have no opinion on that...
I also do not call anyone idiots!! Insult others or blame others for my decisions
All the best
That Image suggests Dell are a partner (of the Consortium) perhaps as a manufacturer/distributor, now that would be interesting!
The OEM is the only piece of the jigsaw that has not been confirmed
All the best going forward
Paul, ( do deepverge need investors who bail at the first hiccup)
I can`t believe you made that statement, probably hundreds
of investors have lost their hard earned cash and you dismiss
them as idiots who don`t know what their doing, are you
the only person on this board, or indeed the market as a
whole who really understands skins?
This graphic is all we need to be concerned with. If we complete even half of this we will be a success. Nothing that we heard on Thursday made us a worse company than we were on Wednesday. There is still a long way to go with this virus and we will have a big part to play in getting back to some kind of normality.
Good posts Retire, Investors should not lose fact of what Deepverge have achieved in the last few months with regards - Merger/Dentistry Trials/Wastewater Detection and unveiling of a brand new product... A staggering achievement..
I would only have one genuine question - How do Deepverge plan to market the Microtox BT system (ie the whole package - Reader/App etc?) am genuinely baffled how this has not been picked up by the media.
With regards the SP drop - Do Deepverge want/need Investors who bail at the slightest hiccup?
Debating questions, no opinion from me on either.
Great reminders retireby40
It’s easy to lose sight within all the noise of how great the tech is and the Huge potential it has.
Fully Invested because of modern water the water treatment/monitoring Side of business, very happy to be mering with integumen though from the great collobration it offers With rinocloud For real time monitoring but also The excellent work being done with Labskin.
Clearly from RNSs which is why I included the dates. It’s a reminder as some seem to forget what’s going on and why the merger is taking place and should be successful.
Retire, where did you cut and paste that from,
apart from first part, nothing new.
I meant H2 for SMIN to be break even or better not H1!
24 Aug from Chairman-
The strategic challenge through this COVID-19 pandemic is being met with the move to provide support services online, making it easier and safer to interact with customers while at the same time to increase the capacity of our equipment to provide surveillance against all sorts of contaminants and threats including viruses and pathogens.
The new platform gives us the ability to fully exploit the data the Company generates from different water systems across the world. Data analytics with the latest AI systems in collaboration with Company partners set Modern Water up for multiple revenue streams from equipment, consumables and predictive services for our existing and new clients coming online to manage their COVID-19 risk. "
The merger looks great value for both to me and the synergies are there for all to see. Yes we’ve had a bumpy few days but given both H2s will be massively up on H1 and likely retrofit revenues early 2021, cash in bank and loan facility things are not dire at all and in fact I’m looking to the future with confidence.
18 June -
Modern Water rolls out surveillance data analytics online technologies
Modern Water, the global water crisis monitoring and solutions provider, announces its intention to strengthen its position in water monitoring by unveiling plans to roll out the latest technologies in data management, analytics and encryption to bring its business and its suite of water monitoring solutions online.
With the award winning Microtox range, capable of monitoring up to 2,700 contaminants, the system collates data that is analysed with built-in artificial intelligence to provide site specific educational insights and over time offers predictive capabilities when incorporated with external systems, such as aggregated weather data.
In addition, the Company has launched a fully integrated eCommerce solution with back-office and logistics platform, allowing clients and partners access to pricing, quotes, and equipment specifications. It has a built-in knowledge centre where 30 years of water contamination monitoring domain expertise is available to all users. Dedicated account areas for clients and partners also provide dashboards showing the live and near-time state of water monitoring sites including up to date information on consumables.
Simon Humphrey, CEO of Modern Water, commented:
"As part of the ecowaterOS [i] consortium and in collaboration with Integumen plc's data division, the Company now has the ability to increase remote surveillance capacity of clients' water contamination monitoring solutions to better protect water systems in a COVID19 world."
This first order from our Indian collaborators builds on, and is complementary to, the recent transformation of the Company's business model that has helped improve sales in our global monitoring division, with its 30 year global footprint of the Microtox range of products and services."
Ajay Popat, President of Ion Exchange (India), added:
"As we said on signing of our collaboration agreement, Modern Water's technology, both brine concentration and forward osmosis, are innovative and the right strategic fit to further improve competitiveness and attractiveness of our Zero Liquid Discharge solutions and brine recovery processes to our customers. We are now ready to move to the first installation as we deepen our working relationship with Modern Water."
Modern Water Microtox LX declared winner in China laboratory instrument award
Modern Water's newest laboratory biotoxicity analyser, Microtox LX [i] , has been announced the Winner of the "Scientific Instrument Excellent New Product" award by the Chinese first scientific instrument professional portal (Instrument.com.cn). The winner was announced in a virtual ceremony of the Instrument Information Network .
The "Scientific Instrument Excellent New Product" selection event is held once a year. Microtox LX was originally shortlisted to 344 instruments in August 2019 by a panel of experts, from more than 9,000 new instruments out of nearly 1,500 companies.
Sichuan Province China orders Modern Water equipment worth cGBP410,000
Modern Water is pleased to announce that it has secured the sale of its largest single order for 20 Microtrace(R) PDV ("PDV") units and 7 sets of related consumables in China. The total value of the order is CNY3.56 million (cGBP410,000). Following a directive from the Sichuan Department of Ecology and Environment Office, the new PDV units, which measure trace metals in water, soil and food, will be used to improve the province's emergency response to environmental emergencies and overcome a shortfall to provide comprehensive analysis on water quality.
Simon Humphrey, CEO of Modern Water, commented:
"Following the 2019 launch in China of Modern Water's award winning Microtox LX laboratory water testing unit and the recent confirmation of the 10 industrial scale Microtox CTM units to be shipped in the 3rd quarter, yet another milestone order size and value for 20 of our new Microtrace PDV portable water contamination test units increases Modern Water's exposure to water health and safety in China.
"All Modern Water equipment require consumables and have the option to be upgraded with AI-As-A-Service offering predictive water contamination alerts based on accumulated historical data that may contribute to increased revenue per client."
Integumen and Modern Water have accelerated the integration of their respective water monitoring equipment and AI based contamination detection abilities following increased orders of the Microtox range in Europe and SE Asia, including back fitting Integumen AI based capabilities to the 10 top-of-the-range Microtox CTM units to be shipped to China in the third quarter of 2020 as announced on 23 December 2019.
Microtox equipment are built to be modular and expandable. Within this hardware capacity Integumen is configuring its RAWTest [i] AI real-time alert solution to expand the capability of the instruments to detect bacteria, nitrates and phosphates. The roadmap for this integration includes the ability to detect viruses such as SARS-Cov-2.
The environmental arm of DEFRA [ii] has confirmed it is looking at wastewater epidemiology and US Centers for Disease Control and Prevention is already monitoring human waste [iii] , the ministry of ecology [iv] in China are mandating the hygiene monitoring of water and wastewater and dormant buildings during the epidemic have built up contaminated water in their pipework [v]
Simon Humphrey, CEO of Modern Water commented:
"The COVID19 public health crisis may have reached its first wave peak, but the next stage of managing future risk of spreading is the early monitoring of water and wastewater. Demand for equipment and our reagents continue to increase and we are delighted to have access to increased production volumes to allow us expand and the integrated AI development programme that enhances the Microtox value, improving revenue per client from existing equipment."
Modern Water is pleased to announce that, following the collaboration agreement with Ion Exchange (India) Ltd (RNS: 23 December 2019 [i] ), an order for stage one of a two stage project with a total value of c. GBP900,000 project has been received. The estimated net value to Modern Water for stage one is approximately GBP50,000 and for both stages is between c. GBP235,000 and c. GBP270,000.
The project consists of an initial pilot plant for the zero-liquid-discharge system of the Company's All-Membrane Brine Concentration ("AMBC") plant and is expected to reduce the operational costs of wastewater treatment for the specialty chemical production facility of our collaboration partner. On completion of stage one, it is intended that a larger plant is to be installed with the smaller pilot AMBC plant to be used for demonstration with our collaboration partner's clients in projects across India, Oman, the United Arab Emirates and Saudi Arabia .
Simon Humphrey, CEO of Modern Water, commented:
"Even with travel restrictions imposed by COVID19, demand for the Company's patented AMBC technology as a critical component of our end-to-end wastewater monitoring and recovery solution is growing.
I hold a sizeable chunk in what will be DPVG and am more than a little disappointed with the action on Thursday afternoon and Friday. I think the presentation was okay and I liked the fact the wider team was involved although the focus on the breathalyser was too much and detracted from water monitoring which is a game changer and our core competence. Yes the test will be great but it’s further down the line and many LF antigen tests are being validated. That said our test needed more time as it’s new so needed explaining although the explanation could’ve been better.
The BoD has been in place for a little over 2 years and has taken revenues from £500k in 2018 (only there for 5 months) to £1m 2019 and reaffirmed £4m guidance 2020 and the share from in old money from 0.5p to 3p.
The twitter use with hindsight probably attracted traders who have no doubt caused even more volatility so that’s a lesson to learn. The lack of media coverage doesn’t concern me as we are only beginning live-virus testing so I’d expect a ramp up after a few weeks and hopefully we get updates via RNS.
I’ve no doubt the real-time roll retrofit roll out will occur early next year and given they’re existing customers I imagine in order some cash will be up front and the remainder on delivery so decent revenues should come in early next year which should fund production for fresh kits for new customers. If we can’t keep up with demand surely with our collaborative business model a partner would be sought.
I expect H1 for SKIN to be break even at worst so over £1m in cash and £3m loan facility. MWG had a poor H1 but remember the 48% increase in reagent orders will be mostly shipped this month and revenues realised this half too. H2 will be a lot better and below are some reasons why MWG and SKIN will be stronger together and anyone thinking MWG is a dud is wrong.
6 May -
Further to the announcement on 30 March 2020 notifying production commencement of the first batch of Modern Water ("MW") reagent, Integumen plc ("Integumen") has commenced s hipping to meet the back-orders and growing demand for water contamination detection bacteria from existing clients. With the increase of water hygiene controls around the world due to the COVID-19 public health crisis, production volume has doubled to a list price value of GBP500,000 per batch. Revenues from sales of reagent produced under the revenue sharing manufacturing agency agreement with Integumen (the "Agreement") will be split 60% / 40% in favour of Modern Water, after costs. The Company expects that that sales of reagent under the Agreement will have a value of at least $1.25m in the current financial year.